The emergence of SARS-CoV-2 in the end of 2019, an aetiologic agent responsible for the 1SARS plunged the world into an unprecedented sanitary crisis. Papers on COVID-19 have been fast-tracked since then.2–5 Accelerated time from submission to publication6–8 and qualitative changes in peer review,9 associated with empirical evidence that duplicate and implausible clinical trials have been carried out during the pandemic,10–12 could perhaps imply lower quality of peer review in COVID-19 research. Accumulating empirical evidence has also been indicating the pandemic era output to be less reliable than its prepandemic counterpart.2 10–14 A systematic review to evaluate the methodological quality of COVID-19 peer-reviewed clinical studies compared with historical controls found methodological quality scores to be lower in COVID-19 articles across all study designs.12 Meanwhile, data sharing practices remained largely unchanged during the first year of the pandemic.13 14 With no mandates of data sharing in place for COVID-19 studies, the reproducibility of these data on COVID-19 is yet to be independently verified as well.2 However, more efficiency in scientific publication did manifest in accelerated publication,6–8 journals tearing down their paywalls for their COVID-19 output,14 an increased usage of life and medical sciences preprint servers to increase speed and transparency,15 not to mention the intense international collaboration that resulted in the development of multiple high-efficacy vaccines within the first year of the pandemic.16 On the other hand, some pratices that reduce the reliability of clinical trials may have gained some traction during 2020, such as executing underpowered studies with small samples, multiplicity of trials testing ideas with low prior probability of being true, forgoing blinding to test interventions10 11 14 17–20 and incomplete reporting of findings, which was already an issue before the pandemic.12 21 To …

中文翻译：

---

一些设计不佳的 COVID-19 研究如何导致巴西的错误信息：以证据为基础的科学传播案例

2019 年底 SARS-CoV-2 的出现，一种导致 1SARS 的病原体使世界陷入了前所未有的卫生危机。从那时起，关于 COVID-19 的论文得到了快速跟踪。2-5 从提交到发表的时间加快 6-8 和同行评审的质变 9，与经验证据相关，即在大流行期间进行了重复和不可信的临床试验， 10-12 可能意味着 COVID-19 研究中同行评审的质量较低。积累的经验证据也表明，大流行时期的产出不如大流行前的产出可靠。